Context and Reporting Period
Context Therapeutics Inc. filed a Form 8-K dated June 15, 2023, with the report signed on June 20, 2023. The filing reports an event under Item 8.01, “Other Events.”
Material Event
Nasdaq notified the company on June 15, 2023 that its common stock had closed at or above the $1.00 minimum bid price for 10 consecutive business days. The company therefore regained compliance with Nasdaq Listing Rule 5550(a)(2), and Nasdaq considered the matter closed.
The company had previously received a January 24, 2023 notice stating that its stock had failed to maintain a $1.00 closing bid price for 30 consecutive business days. The initial compliance period was scheduled to expire July 24, 2023.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
Outlook, Risks, and Unusual Items
The immediate Nasdaq minimum bid price compliance risk described in the filing has been resolved. The filing does not provide additional financial guidance, operating outlook, contingencies, or management commentary.
Key Facts to Verify
- Confirm the company’s continued compliance with Nasdaq’s minimum bid price requirement after the reported compliance date.
- Review subsequent filings for any additional Nasdaq listing requirements or notices.
- Assess the company’s financial condition and funding needs using its periodic reports, as this Form 8-K contains no financial results.